Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Belgium
  4. Euronext Bruxelles
  5. MDxHealth SA
  6. News
  7. Summary
    MDXH   BE0003844611

MDXHEALTH SA

(MDXH)
  Report
Real-time Euronext Bruxelles  -  11:35 2022-11-25 am EST
0.6880 EUR   -3.10%
11/04European ADRs Move Higher in Friday Trading
MT
10/27MDxHealth Reports Q3-2022 Results
GL
10/27MDxHealth Reports Q3-2022 Results
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

MDxHealth Announces Results of its Annual and Extraordinary General Shareholders' Meetings and Resignation of Director

05/25/2022 | 04:01pm EST

NEWS RELEASE - REGULATED INFORMATION
                25 May 2022, 4:00 p.m. EDT / 22:00 CET

MDxHealth Announces Results of its Annual and Extraordinary
General Shareholders’ Meetings and Resignation of Director

IRVINE, CA, and HERSTAL, BELGIUM – 25 May 2022 – MDxHealth SA (Nasdaq and Euronext Brussels: MDXH) ("MDxHealth" or the "Company"), a commercial-stage precision diagnostics company, today held its ordinary annual general shareholders' meeting ("AGM") and an extraordinary general shareholders' meeting ("EGM").

The items on the agenda of the AGM and EGM included the approval of a number of resolutions relating to the financial year ended on 31 December 2021, as well as the issuance of a new share option plan called the "2022 Share Option Plan" and the amendment of article 29 of the Company's articles of association. The proposed resolutions that were submitted to the meetings were all duly passed.

The minutes of the AGM and EGM, and documents that were submitted to the meetings can be accessed via the Company’s website.

After the AGM and EGM were held, Rudi Mariën (as permanent representative of RR-Invest S.à.r.l.) presented to the chair of the board of directors the resignation of RR-Invest S.à.r.l. as non-executive director of the Company, effective as from 26 May 2022.

Michael McGarrity, CEO of MDxHealth, commented “On behalf of our Chairman Koen Hoffman, the Board of Directors and employees of MDxHealth, I would like to thank Rudi Marien for his unwavering support of MDxHealth over many years. Rudi has been a valued resource to me since I joined in 2019 and he will be missed as a member of our Board. I am confident that we will be able to count on Rudi’s support as we move forward to deliver value to all of our stakeholders.”

About MDxHealth®

MDxHealth is a commercial-stage precision diagnostics company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers and prognosis of recurrence risk. The Company's European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and U.S. headquarters and laboratory operations based in Irvine, California. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealthfacebook.com/mdxhealth and linkedin.com/company/mdxhealth.

For more information:

MDxHealth

info@mdxhealth.com

 

Important information
The MDxHealth logo, MDxHealth, ConfirmMDx, SelectMDx, ResolveMDx, AS-MDx and MonitorMDx are trademarks or registered trademarks of MDxHealth SA ("MDxHealth"). All other trademarks and service marks are the property of their respective owners.

Attachment


All news about MDXHEALTH SA
11/04European ADRs Move Higher in Friday Trading
MT
10/27MDxHealth Reports Q3-2022 Results
GL
10/27MDxHealth Reports Q3-2022 Results
AQ
10/27MDxHealth SA Reaffirms Revenue Guidance for the Year 2022
CI
10/27MDxHealth SA Reports Earnings Results for the Third Quarter and Nine Months Ended Septe..
CI
08/29Oppenheimer Adjusts MDxHealth Price Target to $21 From $18, Maintains Outperform Rating
MT
08/26BTIG Adjusts Price Target on MDxHealth to $15 From $13, Reiterates Buy Rating
MT
08/26MDXHEALTH SA : Half-year report
CO
08/25MDxHealth SA Reports Earnings Results for the Half Year Ended June 30, 2022
CI
08/25MDxHealth Reports Half Year 2022 Results
GL
More news
Analyst Recommendations on MDXHEALTH SA
More recommendations
Financials
Sales 2022 40,9 M 42,5 M 42,5 M
Net income 2022 -33,9 M -35,3 M -35,3 M
Net Debt 2022 - - -
P/E ratio 2022 -
Yield 2022 -
Capitalization 112 M 117 M 117 M
Capi. / Sales 2022 2,74x
Capi. / Sales 2023 1,65x
Nbr of Employees 191
Free-Float 84,3%
Chart MDXHEALTH SA
Duration : Period :
MDxHealth SA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MDXHEALTH SA
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Mean consensus -
Number of Analysts 0
Last Close Price 0,69
Average target price
Spread / Average Target -
Managers and Directors
Michael K. McGarrity Chief Executive Officer & Executive Director
Ron Kalfus Chief Financial Officer
Koen Hoffman Chairman
Miriam Reyes Executive Vice President-Operations
Joseph Sollee Chief Compliance Officer, EVP & General Counsel
Sector and Competitors
1st jan.Capi. (M$)
MDXHEALTH SA-22.00%117
MODERNA, INC.-30.55%67 769
IQVIA HOLDINGS INC.-22.03%40 859
LONZA GROUP AG-33.93%39 445
ALNYLAM PHARMACEUTICALS, INC.25.44%26 171
SEAGEN INC.-20.16%22 918